AllSci News
Novartis's remibrutinib beats teriflunomide across Phase III relapsing MS trials
Novartis's remibrutinib has met the primary endpoint in both replicate Phase III trials in relapsing multiple sclerosis (RMS), demonstrating superiority...
BioNTech halts personalized mRNA cancer vaccine trial in CRC after survival imbalance
BioNTech SE (Nasdaq: BNTX) has terminated the Phase II BNT122-01 trial of autogene cevumeran in resected colorectal cancer after an independent data safety...
10x wins USD 4.8m willful-infringement verdict against Qiagen-owned Parse
A federal jury in the US District Court for the District of Delaware has found that Parse Biosciences — now a subsidiary of Netherlands-based Qiagen (NYSE:...
Savolitinib plus Tagrisso hits first-line PFS goal in MET-overexpressing EGFR-mutated lung cancer
The SANOVO Phase III trial has moved savolitinib (Orpathys) plus osimertinib into the first-line EGFR-mutated lung cancer setting, showing a statistically...
Convergen raises USD 15m to advance tau-targeting protein degradation platform
Suzhou-based Convergen has closed a USD 15 million Seed+ financing round to advance its TrimTAC targeted protein degradation platform for neurodegenerative...
EIT Pharma secures USD 35m Series A to advance lonafarnib in hepatitis D
Washington-based EIT Pharma, Inc. has closed an oversubscribed USD 35 million Series A financing round to support the late-stage regulatory review of...
Kazia raises USD 40m upfront, links another USD 80m to breast cancer readouts
Australia-based Kazia Therapeutics Limited (Nasdaq: KZIA) closed an oversubscribed, tranched registered public offering generating USD 40 million in upfront...
PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027
Princeton, New Jersey-based PMV Pharmaceuticals (Nasdaq: PMVP) announced an oversubscribed public offering expected to raise approximately USD 50.8 million...
FDA expands Stelara into pediatric ulcerative colitis with non-TNF mechanism
Stelara (ustekinumab), the anti-IL-12/23 monoclonal antibody marketed by Janssen Biotech, has received US FDA approval for moderately to severely active...
FDA approves Besremi for essential thrombocythemia, first new ET drug in nearly 30 years
The US FDA has approved Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), marking the first new...
RedHill exits Talicia for USD 18m upfront to fund GI portfolio expansion
RedHill Biopharma (Nasdaq: RDHL) has divested its 70% stake in Talicia, an FDA-approved H. pylori eradication therapy, to a subsidiary of Canada-based...
Revelyx launches with recombinant botulinum toxin ready for Phase II readout
Nashville-based Revelyx Bio has launched as a clinical-stage company built around an exclusive license from China-based Chongqing Claruvis Pharmaceutical...
Lilly snaps up Merida in USD 2.9b autoimmune deal
Eli Lilly has agreed to acquire Cambridge, Massachusetts-based Merida Biosciences, Inc., a private precision immunology company, for up to USD 2.875 billion...
Enhertu plus pertuzumab breaks decade-long first-line HER2-positive breast cancer status quo
The European Commission has approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adults with...
Roche bets USD 1.53 billion on Simcere’s trispecific T-cell engager
Roche has agreed to pay Simcere Pharmaceutical Group Limited (HKEX: 02096) USD 75 million upfront for global exclusive rights to SIM0660, a CD79a/CD19/CD3...
The AllSci Brief
Free, systematic R&D and deal news. Daily.